637032-09-8

Basic information

• Product Name: 2-(3,4,5-trimethoxy-phenyl)-thiazolidine-3,4-dicarboxylic acid 3-tert-butyl ester
• Synonyms: 2-(3,4,5-trimethoxy-phenyl)-thiazolidine-3,4-dicarboxylic acid 3-tert-butyl ester
• CAS NO: 637032-09-8
• Molecular Weight: 399.465
• Mol File: 637032-09-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-(3,4,5-trimethoxy-phenyl)-thiazolidine-3,4-dicarboxylic acid 3-tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3,4,5-trimethoxy-phenyl)-thiazolidine-3,4-dicarboxylic acid 3-tert-butyl ester(637032-09-8)
• EPA Substance Registry System: 2-(3,4,5-trimethoxy-phenyl)-thiazolidine-3,4-dicarboxylic acid 3-tert-butyl ester(637032-09-8)

Safety Data

• Hazardous Substances Data: 637032-09-8(Hazardous Substances Data)

Upstream product

• 86-81-7 3,4,5-trimethoxy-benzaldehyde 
• 24424-99-5 di-tert-butyl dicarbonate 
• 72678-94-5 (2RS,4R)-2-(3,4,5-trimethoxyphenyl)-thiazolidine-4-carboxylic acid 

Relevant articles and documents

Synthesis, in vitro structure-activity relationship, and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents

A series of (2RS,4R)-2-arylthiazolidine-4-carboxylic acid amide (ATCAA) was synthesized. Antiproliferative activity against melanoma and prostate cancer cells compared with control cells (fibroblast and RH7777, respectively) was evaluated. Compound 3id sh

Synthesis and antiproliferative activity of thiazolidine analogs for melanoma

We have previously described 2-aryl-thiazolidine-4-carboxylic acid amides as a novel class of antiproliferative agents for prostate cancer. Screening these compounds with melanoma cell lines revealed that several of them have potent antiproliferative activity and selectivity against melanoma. To further improve the potency and selectivity, we synthesized a new series of analogs and tested them in two melanoma cell lines and fibroblast cells (negative controls). Comparison of anticancer effects of these compounds with a standard chemotherapeutic agent, sorafenib, showed that they are very effective in killing melanoma cells with low micromolar to nanomolar antiproliferative activity and provide us a new lead for developing potential drugs for melanoma.